Vaccine Development
The adjuvant CPG 7909 may allow two-dose hepatitis B vaccine regimens
Published in Hepatitis Weekly, March 7th, 2005
"Oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG ODN) act as potent Th1-like immune enhancers with many antigens in animal models. We have extended these observations to the first clinical evaluation of the safety, tolerability and immunogenicity of CPG 7909 when added to a commercial HBV vaccine," investigators in Canada report.
"In a randomized, double-blind phase I dose escalation study, healthy volunteers aged 18-35 years were vaccinated at 0, 4 and 24 weeks by intramuscular injection with Engerix-B (GlaxoSmithKline)," wrote C.L. Cooper and colleagues,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-03-07)
More Articles from Hepatitis Weekly
- Diabetes Risk Factors
Hepatitis C virus infection triggers diabetes in liver graft recipients - Diagnostics
Qualitative multiplex RT-PCR offers simultaneous detection of HIV and HCV - Oncology
Low platelet counts denote multicentricity in HCV-related liver cancer - Transplant Medicine
Adefovir resolves drug-resistant hepatitis B after liver transplantation - Allergy and Immunology
Anhydrase II antibody is not a prognostic marker of autoimmune pancreatitis - Allergy and Immunology
Circulating dendritic cells fall short in hepatitis B virus-infected humans - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
